Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Dexcom ( (DXCM) ) just unveiled an update.
Dexcom announced a leadership transition with Kevin R. Sayer retiring as CEO effective January 1, 2026, and Jacob S. Leach being appointed as the new CEO. The company reported a 15% year-over-year revenue growth in the second quarter of 2025, reaching $1.157 billion, and received FDA clearance for its Dexcom G7 15 Day CGM System, showcasing its continued innovation and strong market position.
The most recent analyst rating on (DXCM) stock is a Buy with a $100.00 price target. To see the full list of analyst forecasts on Dexcom stock, see the DXCM Stock Forecast page.
Spark’s Take on DXCM Stock
According to Spark, TipRanks’ AI Analyst, DXCM is a Outperform.
Dexcom’s strong financial performance and strategic expansion into the type 2 diabetes market are significant strengths. However, valuation concerns due to a high P/E ratio and challenges such as declining gross margins and an FDA warning letter impact the overall score. The company’s strategic initiatives and management confidence, as reflected in the share repurchase program, provide a balanced outlook.
To see Spark’s full report on DXCM stock, click here.
More about Dexcom
Dexcom, founded in 1999, is a leader in glucose biosensing technology, providing innovative solutions for diabetes management. The company focuses on empowering individuals to manage their health through advanced biosensing platforms.
Average Trading Volume: 3,485,923
Technical Sentiment Signal: Hold
Current Market Cap: $35.11B
See more data about DXCM stock on TipRanks’ Stock Analysis page.